Simultaneous Pancreas-Kidney Transplantation: Evaluation of Graft Function, Cholesterol, Triglycerides, and Immunosuppressive Regimens

• Published in: Transplantation proceedings 2009-04, Vol.41 (3), p.916-918
• Main Authors: Stahlschmidt, A, Suzigan, B.H, Martins, C.C, Swarowski, F, Seelig, D.C, Bianco, P.A, Keitel, E, Santos, A.F, Garcia, C.D, Garcia, V.D
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Blood Glucose - metabolism; Cholesterol - blood; Diabetes Mellitus, Type 1 - surgery; Diabetic Nephropathies - surgery; Disorders of blood lipids. Hyperlipoproteinemia; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Glycated Hemoglobin A - metabolism; Humans; Hypolipidemic Agents - therapeutic use; Immunosuppressive Agents - therapeutic use; Kidney Failure, Chronic - surgery; Kidney Transplantation - immunology; Kidney Transplantation - mortality; Kidney Transplantation - physiology; Medical sciences; Metabolic diseases; Pancreas Transplantation - immunology; Pancreas Transplantation - mortality; Pancreas Transplantation - physiology; Patient Selection; Retrospective Studies; Surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Time Factors; Tissue, organ and graft immunology; Treatment Outcome; Triglycerides - blood
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2009.03.037

Abstract Aims To evaluate pancreas graft function, use of insulin, cholesterol, triglyceride levels, prescription of lipid-lowering drugs, and immunosuppressive regimens among recipients of simultaneous pancreas-kidney transplants (SPKT), who had initial immunosuppression with tacrolimus, sirolimus, and corticosteroids. Methods From 2000 to 2007, we performed 73 SKPT, among which we conducted a retrospective data analysis on 51 medical records of patients who had been followed for at least 6 to 72 months. We excluded from the analysis eight recipients who died before 6 months: eight with early pancreas graft losses and six for continued follow-up in other centers. Results There were four pancreas graft losses after 6 months due in two diabetes mellitus recurrence, one posttuberculosis treatment, and one after use of nonsteroidal inflammatory medication. Mean plasma glucose levels ranged from 84 to 103 mg/dL, while glycosylated hemoglobin (HbA1) levels ranged from 5.7% to 6.2%. At 6, 12, 36, and 60 months, 80%, 91%, 86%, and 75% of recipients, respectively, had HbA1 lower than 6.5%. In the same period, 10%, 8%, 10%, and 11% of recipients became insulin-dependent. Mean cholesterol levels (mg/dL) at 6, 12, 36, and 60 month were 190, 180, 196 and 193, while triglyceride levels (mg/dL) were 162, 129, 106, and 113 respectively. Recipient's rate of lipid-lowering drug use was 18%, 21%, 20%, and 22% at 6, 12, 36, and 60 months. Mean serum creatinine levels (mg/dL) with standard deviations were 1.3 ± 0.4, 1.5 ± 0.4, 1.6 ± 0.5, 1.8 ± 0.9, at 6, 12, 36 and 60 months respectively. Nineteen recipients had sirolimus suspended and 14 recipients, tacrolimus suspended as well for various reasons. Conclusion Mean plasma glucose levels were normal during the period. About 10% of recipients became insulin-dependent and 20% required lipid-lowering drugs. The immunosuppressive regimen protocol had to be changed in 60% of patients.